Filtered By:
Therapy: Gene Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 6 results found since Jan 2013.
Gene Therapy Clinical Trial for Mesothelioma Moving Forward
This study will compare the effectiveness of the drug against a control group receiving only the gemcitabine and celecoxib. Patients have a one-in-two chance of being randomly assigned to either the adenovirus treatment or the control group.
Adenovirus-delivered interferon Alpha-2b is designed as a second- or third-line treatment for patients who have failed in earlier regimens. Patients who previously had aggressive mesothelioma surgery but whose tumors have since progressed would be eligible to enroll.
Success at the phase III level would mark the culmination of 20 years of researching and fine tuning gene therapy for us...
Source: Asbestos and Mesothelioma News - September 23, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news
TLR3 Ligand PolyI:C Prevents Acute Pancreatitis Through the Interferon- β/Interferon-α/β Receptor Signaling Pathway in a Caerulein-Induced Pancreatitis Mouse Model
In this study, we have found that polyI:C pretreatment prevents caerulein-induced pancreas edema, neutrophil infiltration, the accumulation of ROS, and inflammatory gene expression in the AP mice models. PolyI:C-triggered IFN-β production and downstream IFNAR signaling activation are required for the suppressive effect of polyI:C in the caerulein-induced AP model. Our study has not only demonstrated the protective role of polyI:C in limiting AP, but has also suggested a potential application of TLR3 ligands in the treatment of AP.
Materials and Methods
Mice and Reagents
Ifnb−/− mice and Ifnar1&#x...
Source: Frontiers in Immunology - May 2, 2019 Category: Allergy & Immunology Source Type: research
Identifying a Murine Xenograft Model Relevant to Light-Chain Specific Approaches to Human Ig Light-Chain Diseases
CONCLUSIONS: The ALMC-1, RPMI 8226 and H929 IP models did not meet the criteria we required in order to effectively test specific interventions on circulating LC (Table 1). The NSG JJN3 IP model had a short latency period for LC, β2M and FLUX measurements, and had significant correlations among these measurements. The NSG JJN3 model met our criteria. We are currently evaluating soluble BCMA levels in this model also, These measurements will allow investigators to distinguish the impact of interventions on LC specifically, independent of tumor cells. We have used this model successfully to test an RNAi approach to redu...
Source: Blood - November 21, 2018 Category: Hematology Authors: Kugelmass, A., Zhou, P., Ma, X., Toskic, D., Godara, A., Warner, M., Lee, L. X., Fogaren, T., Varga, C., Comenzo, R. L. Tags: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy Source Type: research
More and More OR Pubs
Potent, Proven and Frequently PublishedMany labs have used our Opioid Receptor antibodies over the past 10+ years. We are grateful for the many publications and testimonals referencing successful use of these antibodies.Here's a sampling of more recent publications: Wendy M. Walwyn, Wenling Chen, Hyeyoung Kim, Ani Minasyan, Helena S. Ennes, James A. McRoberts, and Juan Carlos G. Marvizón. Sustained Suppression of Hyperalgesia during Latent Sensitization by μ-, δ-, and κ-opioid receptors and α2A Adrenergic Receptors: Role of Constitutive Activity. The Journal of Neuroscience, 6 January 2016, 36(1): 204-221; d...
Source: Neuromics - January 25, 2016 Category: Neuroscience Tags: DOR Antibody Kappa Opioid Receptor Antibodies KOR Antibody MOR Antibody Mu Opioid Receptor antibody Opioid Receptors Antibodies Source Type: news
12 Amazing Things We Learned About The Human Body In 2015
The human body is a source of mystery. But every year, scientists get just a little better at understanding its secrets. Of course, 2015 has been no different. In the past year, researchers have created better access to proven therapies, developed futuristic new technologies that may change the way we approach disease and even enacted more complete disease screening processes to keep us healthy. Read on to learn more. Here’s to more scientific discoveries in 2016! @media (max-width: 969px) { #desktop { display: none; } } @media (min-width: 970px) { #mobile { display: none; } } #g-body-de...
Source: Science - The Huffington Post - December 22, 2015 Category: Science Source Type: news
Gene therapy: Enzymes fix disease genes
Nature 497, 7447 (2013). doi:10.1038/497008c
Genome-editing enzymes can be used to correct patient-specific genetic defects.Mutations in the COL7A1 gene cause the skin-blistering disease recessive dystrophic epidermolysis bullosa, which can be fatal. A team led by Jakub Tolar at the University of Minnesota in Minneapolis engineered enzymes called transcription
Source: Nature - May 1, 2013 Category: Research Tags: Research Highlights Source Type: research
